Analgesic Drug Combinations in Neuropathic Pain (2004)

Canadian Institutes of Health Research (CIHR) (Canada)0 个研究点目标入组 71 人开始时间: 2004年8月31日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Neuropathy attributable to an etiology other than diabetes (e.g. hypothyroidism, vitamin B12 deficiency, connective tissue disease, amyloidosis and toxic exposure)
•2. Presence of a painful condition as severe as, but distinct from, their diabetic neuropathy pain
•3. Pregnancy or lactation
•4. End-stage kidney or liver disease
•5. Moderate to severe heart disease (Myocardial Infarction [MI] within preceding year, unstable angina, cardiac conduction defect or congestive heart failure)
•6. Cardiovascular autonomic neuropathy
•7. Postural hypotension more than 20 mmHg on initial assessment
•8. Baseline mild to severe sedation or ataxia due to required concomitant drugs, or any other cause
•9. Males with urinary symptoms attributable to benign prostatic hypertrophy
•10. Presence of a seizure disorder
•11. Angle-closure glaucoma
•12. Ongoing administration of Monoamine Oxidase (MAO) inhibitors and/or a serious psychiatric disorder as diagnosed by a psychiatrist
•13. Ongoing administration of anticonvulsants which induce cytochrome P450 enzymes (e.g. carbamazepine, oxcarbazepine)
•14. Hypersensitivity to any of the study medications
•15. History of significant abuse of illicit drugs, prescription drugs or alcohol
•16. Lack of a primary physician
•17. Patients who live alone and cannot assure daily contact with a friend, family member or caregiver

发起方

Canadian Institutes of Health Research (CIHR) (Canada)